Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer

PURPOSE: Circulating tumor cell (CTC) enumeration has not been prospectively validated in standard first-line docetaxel treatment for metastatic castration-resistant prostate cancer. We assessed the prognostic value of CTCs for overall survival (OS) and disease response in S0421, a phase III trial o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Goldkorn, Amir, Ely, Benjamin, Quinn, David I., Tangen, Catherine M., Fink, Louis M., Xu, Tong, Twardowski, Przemyslaw, Van Veldhuizen, Peter J., Agarwal, Neeraj, Carducci, Michael A., Monk, J. Paul, Datar, Ram H., Garzotto, Mark, Mack, Philip C., Lara, Primo, Higano, Celestia S., Hussain, Maha, Thompson, Ian Murchie, Cote, Richard J., Vogelzang, Nicholas J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2014
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3970171/
https://ncbi.nlm.nih.gov/pubmed/24616308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.51.7417
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados